Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lifecore Biomedical (LFCR) EBIT Margin: 2009-2025

Historic EBIT Margin for Lifecore Biomedical (LFCR) over the last 16 years, with May 2025 value amounting to 14.62%.

  • Lifecore Biomedical's EBIT Margin rose 894.00% to 14.62% in Q2 2025 from the same period last year, while for May 2025 it was -13.38%, marking a year-over-year decrease of 649.00%. This contributed to the annual value of -13.38% for FY2025, which is 649.00% down from last year.
  • Lifecore Biomedical's EBIT Margin amounted to 14.62% in Q2 2025, which was up 156.91% from -25.68% recorded in Q1 2025.
  • In the past 5 years, Lifecore Biomedical's EBIT Margin ranged from a high of 14.62% in Q2 2025 and a low of -46.89% during Q3 2024.
  • Its 3-year average for EBIT Margin is -14.68%, with a median of -13.66% in 2023.
  • As far as peak fluctuations go, Lifecore Biomedical's EBIT Margin soared by 2,784bps in 2021, and later slumped by 3,889bps in 2022.
  • Lifecore Biomedical's EBIT Margin (Quarterly) stood at 14.41% in 2021, then tumbled by 3,889bps to -24.48% in 2022, then surged by 1,956bps to -4.92% in 2023, then plummeted by 110bps to -6.02% in 2024, then spiked by 894bps to 14.62% in 2025.
  • Its EBIT Margin was 14.62% in Q2 2025, compared to -25.68% in Q1 2025 and -6.02% in Q4 2024.